A5044075501- Immune cells in cancer
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Immune Cell Function and Interaction
- Phagocytosis and Immune Regulation
- Glioma Diagnosis and Treatment
- Epigenetics and DNA Methylation
- Autophagy in Disease and Therapy
- Brain Metastases and Treatment
- Cancer, Hypoxia, and Metabolism
- T-cell and B-cell Immunology
- Histone Deacetylase Inhibitors Research
- Cancer, Stress, Anesthesia, and Immune Response
- Nanoplatforms for cancer theranostics
- Adipokines, Inflammation, and Metabolic Diseases
- Liver physiology and pathology
- Metabolism, Diabetes, and Cancer
- Chemokine receptors and signaling
- Meningioma and schwannoma management
Vrije Universiteit Brussel
2014-2024
Universitair Ziekenhuis Brussel
2023-2024
Molecular Oncology (United States)
2024
VIB-UGent Center for Inflammation Research
2016-2021
Bioengineering Center
2017
VIB-VUB Laboratory Myeloid Cell Immunology
2014
Abstract Various steady state and inflamed tissues have been shown to contain a heterogeneous DC population consisting of developmentally distinct subsets, including cDC1s, cDC2s monocyte-derived DCs, displaying differential functional specializations. The identification functionally tumour-associated (TADC) subpopulations could prove essential for the understanding basic TADC biology envisaging targeted immunotherapies. We demonstrate that multiple mouse tumours as well human harbour...
Macrophages are often prominently present in the tumor microenvironment, where distinct macrophage populations can differentially affect progression. Although metabolism influences function, studies on metabolic characteristics of ex vivo tumor-associated (TAM) subsets rather limited. Using transcriptomic and analyses, we now reveal that pro-inflammatory major histocompatibility complex (MHC)-IIhi TAMs display a hampered tricarboxylic acid (TCA) cycle, while reparative MHC-IIlo show higher...
Patients with advanced melanoma who progress after treatment immune checkpoint-inhibitors (ICI) and BRAF-/MEK-inhibitors (if BRAF V600 mutated) have no remaining effective options. The presence of CD1c (BDCA-1)+ CD141 (BDCA-3)+ myeloid dendritic cells (myDC) in the tumor microenvironment correlates pre-existing recognition responsiveness to checkpoint blockade. synthetic saponin-based adjuvant AS01B enhances adaptive immunity through involvement myDC. In this first-in-human phase I clinical...
Abstract Background Recurrent high-grade glioma (rHGG) lacks effective life-prolonging treatments and the efficacy of systemic PD-1 CTLA-4 immune checkpoint inhibitors is limited. The multi-cohort Glitipni phase I trial investigates safety feasibility intraoperative intracerebral (iCer) postoperative intracavitary (iCav) nivolumab (NIVO) ± ipilimumab (IPI) treatment following maximal safe resection (MSR) in rHGG. Materials methods Patients received 10 mg IV NIVO within 24 h before surgery,...
Abstract Background Radiotherapy (RT) synergizes with immune checkpoint blockade (ICB). CD1c(BDCA-1) + /CD141(BDCA-3) myeloid dendritic cells (myDC) in the tumor microenvironment are indispensable at initiating effector T-cell responses and response to ICB. Methods In this phase II clinical trial, anti-PD-1 ICB pretreated oligometastatic patients (tumor agnostic) underwent a leukapheresis followed by isolation of myDC. Following hypofractionated stereotactic body RT (3 × 8 Gy), were...
2037 Background: Intracerebral (iCer) administration (admin) of ipilimumab (IPI) and nivolumab (NIVO) plus IV NIVO following resection recurrent high-grade glioma (rHGG) was well tolerated showed encouraging overall survival (OS) (J. Duerinck et al. JITC 2021). The safety additional postoperative (postop) bi-weekly intracavitary (iCav) admin or + IPI (: first in human intracranial CTLA-4 blockade) investigated a phase I trial (3+3 design with cohort expansion). Methods: Within 24h prior to...
<h3>Background</h3> Radiotherapy (RT) synergizes with immune checkpoint blockade (ICB), reducing immunosuppression within the tumor microenvironment (TME) and inducing immunogenic cell death (ICD) which can trigger dendritic maturation/activation in vitro. CD1c(BDCA-1)<sup>+</sup>/CD141(BDCA-3)<sup>+</sup> myeloid cells (myDC) TME are indispensable at initiating effector CD8<sup>+</sup>/CD4<sup>+</sup> T-cell responses, response to ICB. This ongoing clinical trial investigates efficacy...
Macrophages are often prominently present in the tumor microenvironment, where distinct macrophage populations can differentially affect progression. Although metabolism of macrophages influences their function, little is known about metabolic characteristics tumor-associated (TAM) subsets. Using transcriptomic and metabolomic analyses, we now reveal that pro-inflammatory MHC-IIhi TAMs display a hampered TCA cycle, while reparative MHC-IIlo show higher oxidative glycolytic metabolism. Both...
<h3>Background</h3> The presence of CD1c (BDCA-1)<sup>+</sup> (cDC2) and CD141 (BDCA-3)<sup>+</sup> (cDC1) conventional dendritic cells (myDC) in the tumor microenvironment (TME) is a necessary prerequisite to induce an effector CD8<sup>+</sup> T cell response for immune checkpoint blockade (ICB).<sup>1-4</sup> AS01<sub>B</sub> adjuvant component commercialized prophylactic shingles vaccine which induces adaptive immunity through recruitment activation cDC1 cDC2.<sup>5-6</sup> Previously,...
Abstract BACKGROUND Intra-operative intracerebral (iCE) administration of ipilimumab (IPI) and nivolumab (NIVO) after resection rGB is safe resulted in encouraging survival (NCT03233152J; Duerinck et al. JITC 2021). METHODS Eligible patients (pts) underwent a maximal followed by iCE 5 mg IPI plus 10 NIVO implantation an Ommaya reservoir through which (10 mg) (cohort defined doses 1-, 5- IPI) were administered intracavitary (iCA) combination with intravenously pre- postoperatively Q2w...